Key Highlights

  • Net loss for the third quarter of 2026 was $94.9 million, compared with $110.8 million a year earlier.
  • Cash, cash equivalents and marketable securities totaled $431.3 million as of September 30, 2026.
  • The company remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026.
  • Topline results from the LUMUS Phase 2b trial in systemic lupus erythematosus were announced.

Alumis Inc. (NASDAQ:ALMS) reported financial results for the quarter ended September 30, 2026, and highlighted recent Business progress on November 12, 2026. The South San Francisco company is a late-stage biopharmaceutical developer focused on immune-mediated diseases. Its lead candidate, envudeucitinib, is an oral TYK2 inhibitor in development for psoriasis and was also studied in lupus. The quarter featured new Phase 3 data and an NDA plan that remains on schedule.

Clinical Progress and Regulatory Timeline

Alumis reported new Phase 3 data showing rapid and durable improvements in plaque psoriasis burden for envudeucitinib. The company said the data presented in October showed early and durable improvement in scalp disease severity, itch resolution and quality-of-life measures. It builds on a 54% PASI 100 response rate observed at 48 weeks, which the company described as the highest publicly reported Week 48 rate among existing and investigational oral psoriasis therapies.

Chief Executive Martin Babler said the company remains on track to submit a new drug application in the fourth quarter of 2026. The company also announced topline results from its LUMUS Phase 2b trial of envudeucitinib in systemic lupus erythematosus. The release does not spell out the detailed efficacy results of the lupus study in its summary.

Financial Results

The net loss for the quarter was $94.9 million, compared with $110.8 million for the same period of 2025. Collaboration Revenue was $1.9 million, compared with $2.1 million a year earlier, and it relates to the company's collaboration and license agreement.

Cash, cash equivalents and marketable securities were $431.3 million at September 30, 2026. Based on its current operating plan, the company said that balance is sufficient to fund operating expenses and Capital Expenditure requirements. The release does not provide a specific runway end date in the headline section.

The company's collaboration revenue relates to an agreement that generates modest income compared with its operating losses. The release reports that revenue declined slightly from the prior year, and the company's largest financial figures come from its clinical and regulatory spending. That spending profile is typical of a late-stage developer preparing a first filing and, for the lupus program, additional study work.

Sector Context

Oral therapies for psoriasis compete with a range of injectable Biologics and oral agents, and the market rewards products that show high skin clearance with manageable safety. Companies in this space often compare results on standard endpoints such as the PASI 100 response rate, which is why the company emphasized its published Week 48 figure.

The TYK2 mechanism places envudeucitinib in a class that has attracted substantial development interest across immune diseases. The company's multi-indication work, including the lupus study, reflects an effort to extend the drug's use beyond psoriasis.

Clinical-stage companies in autoimmune and inflammatory disease often report results across several indications in parallel. Alumis's program is one example of that approach, combining a psoriasis filing with a separate lupus study. The release does not provide a timeline for the lupus program beyond the topline announcement.

Risks and What Lies Ahead

The NDA submission is the company's main near-term milestone, and its timing depends on completing the regulatory package on schedule. Clinical-stage companies also face the possibility that regulators request additional data, which could affect the approval timeline.

The company's cash balance and operating plan will be tested by late-stage costs, and the outcome of the lupus program will influence how the company allocates resources. Readers should watch the NDA filing, any regulatory feedback and the detailed lupus results in future updates.

Final Word

The third quarter shows Alumis reducing its net loss from the prior year while holding a cash balance above $430 million and keeping its fourth-quarter NDA plan on track. The company's psoriasis data and the lupus topline results give it more than one clinical path. The NDA submission and any regulatory response will be the main milestones to follow.